cabotegravir/rilpivirine (Cabenuva)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

* long-acting cabotegravir 200 mg/mL (600 mg) plus rilpivirine 300 mg/ml (900 mg) every 8 weeks (2 injections) IM[1][2] Durg interactions:

More general terms

Components

References

  1. 1.0 1.1 Margolis DA, Gonzalez-Garcia J, Stellbrink HJ et al Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. July 24, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28750935 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31917-7/fulltext
    Boyd MA, Cooper DA Long-acting injectable ART: next revolution in HIV? Lancet. July 24, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28750936 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31962-1/fulltext
    FDA News Release. Jan 21, 2021 FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV. https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv
  2. 2.0 2.1 Saag MS, Gandhi RT, Hoy JF, et al Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. Published online October 14, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33052386 https://jamanetwork.com/journals/jama/fullarticle/2771873
  3. 3.0 3.1 Gandhi RT, Bedimo R, Hoy JF et al Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2022 Recommendations of the International Antiviral Society - USA Panel. JAMA. Published online December 1, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36454551 https://jamanetwork.com/journals/jama/fullarticle/2799240
  4. 4.0 4.1 4.2 4.3 Sax PE et al. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel. JAMA 2024 Mar 1; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/38427337 https://jamanetwork.com/journals/jama/fullarticle/2816037
  5. Cabenuva. extended release injectable suspensions https://cabenuvahcp.com/dosing/every-2-month/
  6. Highlights of Prescribing Information CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF